[Alpha-fetoprotein immunotherapy as a stage of combined treatment of cancer patients].
The paper discusses the preliminary findings on alpha-feto-protein (AFP) treatment of 58 patients with stage III-IV malignancies of different localizations. No influence on neoplastic processes was registered in poorly differentiated cell tumors, nor were any immunological mechanisms of antitumor action triggered on. However, in moderately- and well-differentiated cell tumors, several foci of acute immune inflammation were induced. It is suggested that AFP is responsible for tumor cell apoptosis by freeing antigenic determinants from shielding antibodies via elimination of <<immunological enhancement>> of tumor growth.
Chereshnev
V A
VA
Rodionov
S Iu
SIu
Vasil'ev
N V
NV
Orlov
O A
OA
Cherkasov
V A
VA
D017209:Apoptosis; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000473:pathology / Q000628:therapy*; D000509:alpha-Fetoproteins / Q000627:therapeutic use*
D000509:alpha-Fetoproteins